NCT04133090

Brief Summary

The purpose of the present study was to assess the effect of injectable platelet-rich fibrin (i-PRF) enriched with allograft on alveolar bone regeneration when compared with autogenous block bone graft, in the same participants. The study was designed as a split-mouth randomized controlled trial. The patients were randomly assigned to one of two surgical groups: the test group with i-PRF enriched particulate allograft using the screw tent-pole technique; and the control group with autogenous block bone harvested from the ramus area. All augmentation sites covered by leukocytes-PRF (L-PRF) membrane. The primary outcome variable of this study was the radiographic and histologic data collected at postoperative 6 months. The secondary outcome variable was nerve alterations and implant survival.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2016

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 11, 2016

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 8, 2018

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 6, 2019

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 16, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 21, 2019

Completed
Last Updated

January 18, 2020

Status Verified

January 1, 2020

Enrollment Period

2.5 years

First QC Date

October 16, 2019

Last Update Submit

January 14, 2020

Conditions

Keywords

Bone augmentationAutogenous block bone graftLeukocytes and platelet-rich fibrinInjectable platelet rich fibrinTent-pole technique

Outcome Measures

Primary Outcomes (2)

  • Assessment of radiological changes

    Radiologic analysis was performed to compare the changes in height of alveolar bone between the study groups

    Change of alveolar bone height at 6 months

  • Histological assessment

    Bone core samples were harvested from the implant placement sites for calculate the relative quantification of newly-formed bone within both groups as a percentage

    Postoperatively 6 months

Secondary Outcomes (2)

  • Clinical assessment

    6 months, 12 months

  • Clinical assessment

    1 month, 6 months, 12 months

Study Arms (2)

Autogenous block bone graft

ACTIVE COMPARATOR

Surgical site as control group was treated with autogenous block bone graft. Augmentation site was covered with a mixture of particulate allograft and leukocyte and platelet-rich fibrin (L-PRF) membrane.

Procedure: Autogenous block bone graft

i-PRF enriched allograft material+screw tent pole technique

ACTIVE COMPARATOR

Surgical site as test group was treated with injectable platelet rich-fibrin (i-PRF) enriched allograft material. To avoid soft tissue collapse, screws were used. Augmentation site was covered with leukocyte and platelet-rich fibrin (L-PRF) membrane.

Procedure: i-PRF enriched allograft material+ screw tent pole technique

Interventions

Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.

Autogenous block bone graft

The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.

i-PRF enriched allograft material+screw tent pole technique

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who refused to use a partially removable prosthesis and requested dental implant treatment,
  • Patients had bilateral, moderate or severe posterior atrophic mandible,
  • Patients had precluded conditions suitable for short dental implant.

You may not qualify if:

  • Patients who had systemic diseases (osteoporosis, hemophilia, anemia, etc.),
  • Patients who required drugs (bisphosphonate or steroid therapy),
  • Patients who had a smoking habit,
  • Patients who had received radiation therapy within the last two years,
  • Patients who were under 18 years old, pregnant or lactating,
  • Patients who had a total platelet count lower than 150,000/mm3.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Alveolar Bone Loss

Condition Hierarchy (Ancestors)

Bone ResorptionBone DiseasesMusculoskeletal DiseasesPeriodontal AtrophyPeriodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Split-mouth study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer

Study Record Dates

First Submitted

October 16, 2019

First Posted

October 21, 2019

Study Start

April 11, 2016

Primary Completion

October 8, 2018

Study Completion

July 6, 2019

Last Updated

January 18, 2020

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will not share